Baxter International (NYSE:BAX) is set to release its earnings data before the market opens on Thursday, April 26th. Analysts expect Baxter International to post earnings of $0.64 per share for the quarter. Baxter International has set its Q1 guidance at $0.60-0.62 EPS and its FY18 guidance at $2.72-2.80 EPS.
Baxter International (NYSE:BAX) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.77 billion. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.57 earnings per share. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
NYSE BAX opened at $67.22 on Thursday. The company has a market capitalization of $35,805.80, a PE ratio of 27.10, a PEG ratio of 1.81 and a beta of 0.80. Baxter International has a 1-year low of $52.38 and a 1-year high of $72.58. The company has a current ratio of 2.57, a quick ratio of 2.05 and a debt-to-equity ratio of 0.38.
Baxter International declared that its board has authorized a stock repurchase plan on Tuesday, February 20th that permits the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.
In other Baxter International news, Director Carole J. Shapazian sold 4,990 shares of Baxter International stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $66.05, for a total value of $329,589.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Peter S. Hellman sold 3,760 shares of Baxter International stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $64.74, for a total value of $243,422.40. Following the completion of the sale, the director now owns 25,522 shares in the company, valued at approximately $1,652,294.28. The disclosure for this sale can be found here. Insiders sold 27,500 shares of company stock worth $1,783,512 in the last 90 days. Company insiders own 0.07% of the company’s stock.
Several research firms have recently weighed in on BAX. ValuEngine upgraded Baxter International from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Tuesday, April 3rd. Barclays lifted their price objective on Baxter International from $73.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. BMO Capital Markets lifted their price objective on Baxter International from $74.00 to $77.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $72.00 price objective on shares of Baxter International in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Baxter International has a consensus rating of “Buy” and an average target price of $71.13.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.